title: High MET gene copy number predicted poor prognosis in primary intestinal diffuse large B-cell lymphoma.
abstract: BACKGROUND
  MET is a proto-oncogene with its copy number (CN) alterations been reported in some cancers, but not in primary intestinal diffuse large B-cell lymphoma (PI-DLBL) yet.
  
  
  METHODS
  In this retrospective study, we performed histology and chart reviews, immunohistochemistry and quantitative polymerase chain reaction for MET CN alterations on 28 surgically resected PI-DLBLs.
  
  
  RESULTS
  There were 12 men and 16 women with a median age of 70 and a mean follow-up of 32 months. The median MET CN was 2.20 (range, 1.04 to 3.35). CN gain was observed in 11 cases, including 5 with CN greater than 3. Nine patients (32%) had diploid CN and eight (29%) with CN loss. Patients with gain or diploid CN showed significantly worse prognosis (P = 0.046) than those with CN loss. Furthermore, MET CN greater than 3 was associated with an adverse outcome (P = 0.003). Intestinal perforation at presentation was the sole clinicopathological factor associated with a poor prognosis (P = 0.004) and perforation was correlated with CN greater than 3 (P = 0.002).
  
  
  CONCLUSIONS
  Our finding of MET CN gain as a poor prognostic factor in PI-DLBL patients might serve as the rationale for targeting MET signaling pathway in the treatment of these patients.
authors: Department of Pathology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan.
authors: Wan-Ting
authors: WT
authors: Huang
authors: Shih-Sung
authors: SS
authors: Chuang
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000032:analysis; D001706:Biopsy; D016009:Chi-Square Distribution; D056915:DNA Copy Number Variations; D005260:Female; D018628:Gene Dosage; D020022:Genetic Predisposition to Disease; D006801:Humans; D007150:Immunohistochemistry; D007414:Intestinal Neoplasms / Q000737:chemistry / Q000150:complications / Q000235:genetics* / Q000401:mortality / Q000601:surgery; D007416:Intestinal Perforation / Q000209:etiology; D053208:Kaplan-Meier Estimate; D016403:Lymphoma, Large B-Cell, Diffuse / Q000737:chemistry / Q000150:complications / Q000235:genetics* / Q000401:mortality / Q000601:surgery; D008297:Male; D008875:Middle Aged; D010641:Phenotype; D011379:Prognosis; D000090063:Proto-Oncogene Mas; D019859:Proto-Oncogene Proteins c-met / Q000235:genetics*; D060888:Real-Time Polymerase Chain Reaction; D012189:Retrospective Studies; D012307:Risk Factors; D013997:Time Factors
chemical_list: D014408:Biomarkers, Tumor; C000715470:MAS1 protein, human; D000090063:Proto-Oncogene Mas; C491743:MET protein, human; D019859:Proto-Oncogene Proteins c-met
references: BMC Cancer. 2007 Dec 18;7:226
references: 18088415
references: J Clin Oncol. 2011 Dec 20;29(36):4789-95
references: 22042954
references: Blood. 2001 Feb 15;97(4):1063-9
references: 11159538
references: Curr Opin Cell Biol. 2009 Apr;21(2):304-10
references: 19328671
references: J Clin Oncol. 2011 Dec 20;29(36):4803-10
references: 22042947
references: Leuk Res. 2004 Jun;28(6):595-604
references: 15120936
references: Curr Opin Investig Drugs. 2010 Dec;11(12):1477-90
references: 21154129
references: Eur J Cancer. 2010 May;46(7):1260-70
references: 20303741
references: J Clin Oncol. 2011 Dec 20;29(36):4837-8
references: 22042966
references: Blood. 2004 Jan 1;103(1):275-82
references: 14504078
references: Lab Invest. 2010 Sep;90(9):1346-56
references: 20531293
references: Oncogene. 2007 Feb 26;26(9):1276-85
references: 17322912
references: J Thorac Oncol. 2008 Apr;3(4):331-9
references: 18379349
references: Mol Cancer Ther. 2010 May;9(5):1244-55
references: 20423996
references: Clin Cancer Res. 2005 Sep 1;11(17):6177-85
references: 16144918
references: Br J Haematol. 2002 Dec;119(3):672-6
references: 12437643
references: Blood. 2006 Jan 15;107(2):760-8
references: 16189274
references: Nature. 2010 Feb 18;463(7283):899-905
references: 20164920
references: Leukemia. 2003 Apr;17(4):764-74
references: 12682635
references: Mol Cancer Ther. 2005 Dec;4(12):1867-79
references: 16373702
references: Oncol Rep. 2011 Jun;25(6):1517-24
references: 21424128
references: Histopathology. 2008 Oct;53(4):432-40
references: 18983608
references: Oncology. 1998 Sep-Oct;55(5):475-81
references: 9732228
references: Hum Mutat. 2006 Nov;27(11):1115-21
references: 16955415
references: Eur J Haematol. 2010 Apr;84(4):332-6
references: 20015241
references: Science. 2007 May 18;316(5827):1039-43
references: 17463250
references: Biochim Biophys Acta. 2010 Dec;1806(2):208-19
references: 20655987
references: Leukemia. 2000 Feb;14(2):285-91
references: 10673746
references: Blood. 1996 Nov 15;88(10):3998-4004
references: 8916966
references: Br J Haematol. 2004 Nov;127(3):305-7
references: 15491290
references: Nat Rev Drug Discov. 2008 Jun;7(6):504-16
references: 18511928
references: Nat Rev Mol Cell Biol. 2003 Dec;4(12):915-25
references: 14685170
references: J Clin Oncol. 2009 Apr 1;27(10):1667-74
references: 19255323
references: Neoplasma. 2010;57(1):29-34
references: 19895169
references: Eur J Haematol. 2003 May;70(5):282-9
references: 12694163
references: Mol Cancer Ther. 2003 Nov;2(11):1085-92
references: 14617781